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Toxin-coregulated pilin A (TcpA) is the main structural subunit of a type IV bundle-forming pilus of Vibrio
cholerae, the cause of cholera. Toxin-coregulated pilus is involved in formation of microcolonies of V. cholerae
at the intestinal surface, and strains of V. cholerae deficient in TcpA are attenuated and unable to colonize
intestinal surfaces. Anti-TcpA immunity is common in humans recovering from cholera in Bangladesh, and
immunization against TcpA is protective in murine V. cholerae models. To evaluate whether transcutaneously
applied TcpA is immunogenic, we transcutaneously immunized mice with 100 g of TcpA or TcpA with an
immunoadjuvant (cholera toxin [CT], 50 g) on days 0, 19, and 40. Mice immunized with TcpA alone did not
develop anti-TcpA responses. Mice that received transcutaneously applied TcpA and CT developed prominent
anti-TcpA immunoglobulin G (IgG) serum responses but minimal anti-TcpA IgA. Transcutaneous immuni-
zation with CT induced prominent IgG and IgA anti-CT serum responses. In an infant mouse model, offspring
born to dams transcutaneously immunized either with TcpA and CT or with CT alone were challenged with 106
CFU (one 50% lethal dose) wild-type V. cholerae O1 El Tor strain N16961. At 48 h, mice born to females
transcutaneously immunized with CT alone had 36%  10% (mean  standard error of the mean) survival,
while mice born to females transcutaneously immunized with TcpA and CT had 69%  6% survival (P < 0.001).
Our results suggest that transcutaneous immunization with TcpA and an immunoadjuvant induces protective
anti-TcpA immune responses. Anti-TcpA responses may contribute to an optimal cholera vaccine.
Cholera, a severe, dehydrating diarrhea in humans, is caused
by the gram-negative bacterium Vibrio cholerae. Strains of V.
cholerae that produce cholera belong to serogroup O1 or O139.
V. cholerae O1 is comprised of two biotypes, classical and El
Tor. Globally, O1-associated cholera is caused by the El Tor
biotype. Cholera toxin (CT), the cause of the severe secretory
diarrhea seen in cholera, is the major virulence factor for all
toxigenic strains of V. cholerae (4). Toxin-coregulated pilus
(TCP) is a second major virulence factor of V. cholerae. The
major structural protein of this pilus, toxin-coregulated pilin A
(TcpA), is encoded by tcpA, and its expression is regulated in
V. cholerae in parallel to cholera toxin (39). TCP is essential for
colonization and virulence in both animal models and human
volunteers (18, 39), and recent data support its role in biofilm
formation and binding to chitinous surfaces in aquatic envi-
ronments (30). Although TcpA from El Tor and classical
strains are approximately 80% homologous at the amino acid
level, monoclonal antibodies have shown epitope differences
between these proteins (19, 22, 31, 36). TcpA proteins from El
Tor and O139 strains are identical (31).
A number of observations suggest that immune responses to
TcpA may contribute to protection against V. cholerae infection.
TcpA has been shown to be essential for V. cholerae colonization
in both mice and humans (18, 39), tcpA mRNA is up-regulated
during early human infection (27), and systemic and mucosal
anti-TcpA immune responses occur in over 90% of individuals
infected with V. cholerae O1 El Tor in Bangladesh (1, 16). Fur-
thermore, passive administration of both polyclonal and mono-
clonal antibodies against TcpA in mice is fully protective against
V. cholerae challenge (36, 37), and active parenteral immunization
of adult female mice with a TcpA peptide along with an immu-
noadjuvant induces protection against V. cholerae challenge of
mice born to immunized mothers (42).
For safety reasons, cholera vaccines that are available or
under development all lack CT. However, CT is a potent im-
munoadjuvant, and immune responses induced by cholera vac-
cines are often less prominent than those induced by wild-type
infection (32). Immunization strategies that augment immune
responses to critical virulence factors may thus contribute to
the development of an optimal cholera vaccine. One approach
to stimulating protective immune responses to specific antigens
is transcutaneous immunization (TCI), a procedure in which
an antigen is applied topically to skin (9, 11). Direct applica-
tion of antigens to skin often fails to induce prominent immune
responses, however, and coapplication of an immunoadjuvant
(usually an ADP-ribosylating protein such as CT or heat-labile
enterotoxin of Escherichia coli) is often required to induce
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robust immune responses (10). TCI is thought to target antigen
to Langerhans cells in the epidermis, which subsequently carry
antigen to draining lymph nodes. TCI has been safe and well-
tolerated in both animals and humans and has generated
strong systemic immune responses in both (9, 11, 12, 44). TCI
is also capable of eliciting mucosal immune responses, includ-
ing inducing antigen-specific immunoglobulin A (IgA) anti-
body-secreting cells in circulation 1 week after topical applica-
tion of antigen and inducing antigen-specific secretory IgA in a
variety of mucosal sites in animals and humans (10, 12). In
order to assess whether TCI would induce immune responses
protective against cholera, we transcutaneously immunized
mice with TcpA with or without the immunoadjuvant CT,
measured anti-TcpA immune responses, and evaluated protec-
tion afforded by transcutaneous immunization with TcpA in a
mouse cholera challenge model.
(The results of this study were presented in part at the 40th
U.S.-Japan Cholera and Other Bacterial Enteric Infections
Joint Panel Meeting, Boston, Mass., November 2005, and the
54th Annual Meeting of the American Society of Tropical
Medicine and Hygiene, Washington, D.C., December 2005.)
MATERIALS AND METHODS
Bacterial strains and media. We used an E. coli Origami strain (Novagen) for
production of recombinant TcpA and wild-type El Tor Inaba V. cholerae O1
strain N16961 for the infant mouse challenge experiments. Both strains were
maintained at 80°C in Luria-Bertani (LB) broth containing 15% glycerol. LB
cultures contained streptomycin (100 g/ml), ampicillin (100 g/ml), tetracycline
(12.5 g/ml), or kanamycin (25 g/ml), as appropriate.
Purification of TcpA. We amplified via PCR DNA encoding TcpA (nucleo-
tides 160 to 675) from V. cholerae strain C6706 by using oligonucleotides 5-G
CTCATATGGATTCGCAGAATATGACTAAGGCTGC-3 (forward primer)
and 5-CCGCTCGAGTTAACTGTTACCAAAAGCTACTGTGAAT-3 (re-
verse primer) and gel purified the product using a gel extraction kit (QIAGEN,
Valencia, CA). We then digested the product with NdeI and XhoI and gel
purified again. We ligated the resultant fragment into pET-15b (Novagen, San
Diego, CA) downstream of and in frame with the N-terminal His tag. The His tag
extension contains a thrombin cleavage site and comprises a total of 21 residues;
the final TcpA molecule lacks the prepilin peptidase cleavage site and 28 amino
acids from the amino terminus of the mature TcpA molecule. We transformed
the pET-15b vector into E. coli Origami cells. We diluted overnight LB broth
cultures of this strain into fresh medium containing ampicillin, tetracycline, and
kanamycin and grew cultures at 37°C with shaking at 220 rpm until an optical
density at 600 nm of 0.6 was reached. We induced TcpA expression with 0.01 mM
isopropyl -D-thiogalactopyranoside (IPTG), growing cells overnight at 30°C at
220 rpm. We then lysed cells by sonication and purified TcpA from the super-
natant by using metal affinity chromatography (BD Talon metal affinity resin; BD
Biosciences/Clontech, Mountain View, CA) followed by gel filtration on a
HiPrep Sephacryl S-100 column (Amersham Biosciences, Little Chalfont, Buck-
inghamshire, England). We concentrated the resulting product by using a Cen-
triplus concentrator (Millipore, Billerica, MA) to 1.5 mg/ml in a buffer contain-
ing 50 mM NaH2PO4 and 300 mM NaCl (pH 7.0) and assessed product purity by
polyacrylamide gel electrophoresis and Coomassie staining and product identity
by Western immunoblotting using rabbit anti-TcpA antisera (Fig. 1).
Immunization of mice. We transcutaneously immunized cohorts of three to
five adult CD-1 mice (Charles River Laboratories) with 50 g of CT (List
Biological Laboratories, Campbell, CA), 100 g of TcpA, or 50 g of CT and 100
g of TcpA on day 0. We administered subsequent transcutaneous immuniza-
tions to mice on days 19, 40, 82, 131, and 161. We performed transcutaneous
immunizations as described previously (34). Briefly, we shaved mice on the
dorsum by using a clipper with a no. 40 blade (Wahl Clipper Corp., Sterling, IL).
Following shaving, we rested the mice for 48 h. We then anesthetized groups of
three to five mice with an intraperitoneal injection (0.40 mg/g of body weight) of
2,2,2-tribromoethanol (Avertin; Aldrich, St. Louis, MO) to prevent grooming
following immunization. In order to enhance absorption of reagents into the
skin, we stripped the shaved area of skin with 3M tape 15 times, replacing tape
every five times (to remove the outer layers of the stratum corneum). We then
hydrated stripped skin for 5 min with water, blotted the region dry, and imme-
diately applied 50 g CT and/or 100 g TcpA to an 1-cm2 shaved-skin surface
area. Our use of animals complied with relevant institutional regulations, guide-
lines, and policies.
Immunological sampling. We collected blood samples from mice on days 0, 18,
33, 54, 81, 96, and 145. We collected stool samples on day 168. All samples were
collected, processed, aliquoted, and stored as described previously (7, 21, 33).
Detection of immune responses. To detect antibody responses to TcpA, we
coated microtiter plates overnight at room temperature with 50 ng of TcpA per
well in 50 mM carbonate buffer (pH 9.6) and subsequently blocked the plates for
1 h at 37°C with phosphate-buffered saline (PBS)–1% ovalbumin (Sigma, St.
Louis, MO). We added dilutions of sera (IgG, 1:1,000; IgA, 1:200) in PBS-0.1%
ovalbumin-0.05% Tween 20 (Sigma) and incubated plates at 37°C for 1.5 h. We
washed the plates and applied sheep anti-mouse IgG conjugated to horseradish
peroxidase (HRP) (Amersham Biosciences) or goat anti-mouse IgA conjugated
to HRP (Southern Biotech, Birmingham, AL) to each well. We then reincubated
plates at 37°C for 1.5 h, washed them with PBS-0.05% Tween 20 (PBS-T), and
developed them with a 0.55-mg/ml solution of 2,2-azinobis(3-ethylbenzthiazo-
line-6-sulfonic acid) (ABTS) (Sigma) with 0.03% H2O2 (Sigma). We then de-
termined the optical density at 405 nm kinetically with a Vmax microplate reader
(Molecular Devices Corp., Sunnyvale, CA) and read plates for 5 min at 14-s
intervals, reporting the maximum slope for an optical density change of 0.2 U as
millioptical density units per minute, as previously described (21).
To detect antibody responses to CT, we sequentially coated microtiter plates
with 1 g of type III ganglioside (Sigma) in 50 mM carbonate buffer (pH 9.6)
overnight and 100 ng CT (List Biological Laboratories, Campbell, CA) per well
in PBS overnight. We then blocked these plates for 4 to 6 h at room temperature
with PBS-1% ovalbumin. We added dilutions of sera (IgG, 1:5,000; IgA, 1:200)
in PBS-0.1% ovalbumin-0.05% Tween 20 and incubated the plates overnight at
room temperature. We then washed the plates and applied sheep anti-mouse
IgG conjugated to HRP or goat anti-mouse IgA conjugated to HRP to each well.
We incubated the plates at 37°C for 1 h, washed them with PBS-T, and developed
them as described above.
To detect specific IgA antibody in stool, we first measured total stool IgA in
samples. Duplicate serial twofold dilutions of stool samples (1:10 to 1:320) in
PBS-T were added to wells previously coated with rat monoclonal anti-mouse
IgA antibody C10-3 (Pharmingen, San Diego, CA) at a dilution of 1:1,000 (33).
We then added a 1:1,000 dilution of goat anti-mouse IgA HRP-linked antibody
to wells and developed the plates as described above. Comparisons were made to
a mouse IgA standard (Kappa TEPC 15; Sigma). To detect specific anti-CT or
anti-TcpA antibodies in stool, we added 75 ng of total stool IgA in PBS-T to wells
in enzyme-linked immunosorbent assays identical to those used to measure
serum anti-CT or anti-TcpA responses, and we processed these plates as de-
scribed above.
Determination of immunization efficacy by use of the infant mouse challenge
model. To establish a 50% lethal dose (LD50) for V. cholerae N16961 among
offspring of unimmunized mice, we first inoculated 3- to 5-day-old CD-1 suckling
mice born to unimmunized mothers with a range of V. cholerae N16961. In brief,
when neonatal pups were 3 to 5 days old, we removed them from their mothers
at least 3 h prior to inoculation. We then intragastrically administered a 50-l
dose containing 2  105 to 2  108 CFU of wild-type El Tor V. cholerae N16961
FIG. 1. Western immunoblot analysis of purified TcpA-His used in
transcutaneous immunization (probed with polyclonal rabbit anti-
TcpA antiserum). Lines to the left indicate positions and molecular
masses of protein standards. TcpA-His, 19.7 kDa.
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(n  5 to 35 mice/cohort). Following oral challenge, we kept neonates separate
from dams at 30°C. We monitored animals every 3 to 6 h for 48 h and, after 48 h,
euthanized any surviving animals. Using this protocol, we established that 106
CFU of V. cholerae N16961 resulted in 50% survival in offspring of unimmunized
adult mice at 48 h (neonatal cohort size, 35 mice). Next, to determine if trans-
cutaneous immunization with TcpA resulted in protection in neonatal mice born
to dams immunized with TcpA and immunoadjuvant (CT) versus immunoadju-
vant alone, we mated adult immunized CD-1 mice following the fourth transcu-
taneous immunization and boosted gravid mice 1 to 2 weeks prior to expected
delivery (42). When neonatal pups were 3 to 5 days old, we removed them from
their mothers at least 3 h prior to inoculation. We then intragastrically admin-
istered a 50-l dose containing 2  106 CFU of wild-type El Tor V. cholerae
N16961, representing approximately one LD50, monitored animals every 3 to 6 h
for 48 h, and, after 48 h, euthanized any surviving animals.
Statistics and graphs. We performed statistical analysis for comparison of
means by using unpaired, two-tailed Student t tests. We calculated survival curves
by using the Kaplan-Meier method and compared data from different experi-
mental groups by using the log rank test. We performed all statistical analysis
using Statistica for Windows, version 6.1 (StatSoft, Inc., Tulsa, OK), and plotted
data using Statistica and Microsoft Excel 2002.
RESULTS
Systemic and mucosal anti-TcpA and anti-CT antibody
responses in mice transcutaneously immunized with TcpA
and/or CT. In order to determine whether transcutaneous
immunization with TcpA and an immunoadjuvant would
elicit systemic anti-TcpA immune responses, we compared
immune responses in sera collected on day 54 from mice
given three transcutaneous immunizations of CT alone, CT
and TcpA, or TcpA alone. Immunization with TcpA in the
absence of CT did not induce a significant anti-TcpA IgG
response. However, mice immunized with TcpA and CT had
robust anti-TcpA IgG responses compared with mice immu-
nized with TcpA alone (P 	 0.01) or CT alone (P 	 0.05)
(Fig. 2A). We observed no significant anti-TcpA IgG in the
group given TcpA and CT on day 33 (data not shown),
indicating that three immunizations were necessary to pro-
duce a significant systemic response. Further immunizations
on day 40 and later increased anti-TcpA IgG responses for
the group immunized with TcpA and CT but not for either
of the groups immunized with TcpA alone or CT alone.
Interestingly, transcutaneous application of TcpA did not
elicit a significant IgA response in day 54 serum either in the
presence or in the absence of an immunoadjuvant (Fig. 2B).
The administration of further booster immunizations did
not alter this observation.
Mice that were transcutaneously immunized with CT or CT
and TcpA developed significant serum IgG (P 	 0.001) and
IgA (P 	 0.01) anti-CT responses compared to mice that were
transcutaneously immunized with TcpA alone (Fig. 2C and D,
respectively). Analysis of day 145 serum revealed that addi-
tional boosting, while raising serum IgG and IgA anti-CT levels
overall, did not change the relative magnitudes of anti-CT
responses in the three vaccine groups.
We did not observe significant anti-TcpA or anti-CT IgA
responses in stool (data not shown).
FIG. 2. Serum anti-TcpA IgG (A), anti-TcpA IgA (B), anti-CT IgG (C), and anti-CT IgA (D) responses. Shown are enzyme-linked immu-
nosorbent assay results of day 54 serum samples from mice that received CT alone (CT), TcpA alone (TcpA), or CT and TcpA (TcpACT)
transcutaneously on days 0, 19, and 40. Columns represent geometric means from reading of samples, in millioptical density units per minute
(mOD/min), and error bars indicate standard errors of the means.
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Neonatal mouse challenge. We first established that 106 CFU
of V. cholerae N16961 represented one LD50 in neonatal mice
born to unimmunized dams. Then, to determine whether trans-
cutaneous immunization with TcpA was protective against wild-
type V. cholerae challenge, we used a modification of the infant
mouse challenge model in which protection is measured in neo-
natal mice born to immunized mothers (42). After a minimum of
four immunizations, we mated female mice and boosted them
approximately 1 to 2 weeks prior to estimated delivery date. We
then challenged pups born to these mothers with one LD50 (2 
106 CFU) of V. cholerae N16961 and monitored the neonatal
mice for survival over the next 48 h. At 48 h, mice born to females
transcutaneously immunized with CT alone had 36% 
 10%
(mean 
 standard error) survival, while mice born to females
transcutaneously immunized with TcpA and CT had 69% 
 6%
survival (P 	 0.001) (Fig. 3).
DISCUSSION
Interactions of toxigenic V. cholerae O1 and O139 bacteria
with the intestinal surface of humans are complex and at least
involve a newly recognized secreted molecule within the TCP
operon, TcpF, as well as TcpA (24, 26). TcpA is the main
structural unit of a bundle-forming pilus involved in micro-
colony formation of V. cholerae at the intestinal surface, and
although TcpA apparently does not mediate direct contact of
V. cholerae organisms to the intestinal surface, strains of V.
cholerae deficient in TcpA are markedly attenuated and unable
to colonize intestinal surfaces, suggesting that microcolony for-
mation is required for full bacterial adherence and virulence
(6, 18, 25, 35, 38–40). TCP is also the receptor for the filamen-
tous bacteriophage that encodes cholera toxin (designated
CTX) (41) and appears to be involved in V. cholerae biofilm
production on chitinous surfaces in aquatic environments (30).
TCP is encoded on a 40-kb pathogenicity island (23), and
expression of the genes in the TCP island, as well as expression
of cholera toxin, is coordinately regulated by two pairs of
membrane-localized proteins, ToxR/ToxS and TcpP/TcpH (3,
8), that both act via a common downstream regulatory protein
within the TCP island, ToxT (8). During in vitro growth, ex-
pression of this virulence regulon requires specific environ-
mental conditions for both the classical and the El Tor biotype
of V. cholerae O1 (28). Recent work has demonstrated up-
regulation of tcpA mRNA during infection of the upper human
intestine (27), and TcpA was recently identified as an immu-
nogenic antigen expressed in vivo during V. cholerae infection
of humans in Bangladesh (16).
Some previous studies examining patients with cholera for
immune responses to TcpA have either examined North
American volunteers challenged with the classical biotype of V.
cholerae O1 or utilized classical TcpA for immunoassays of
patients infected with El Tor V. cholerae O1; these studies have
shown low rates of seroconversion (15). Because classical and
El Tor TcpA proteins share only 80% amino acid identity,
however, these previous studies may have underestimated im-
mune responses to TcpA in patients infected with El Tor V.
cholerae O1, the current strain of pandemic cholera. Indeed,
using El Tor TcpA as the antigen, we have recently docu-
mented systemic and mucosal anti-TcpA immune responses in
over 90% of individuals infected with V. cholerae O1 El Tor in
Bangladesh (1). Whether recurrent antigenic exposure and
anamnestic responses contribute to the differences in immune
responses observed between North American volunteers and
patients who reside in areas where V. cholerae is endemic is
currently unclear.
None of the cholera vaccines currently available or under
development is yet able to reproduce the level of immunity
seen following natural infection, and although not systemati-
cally assayed, none would be expected to induce anti-TcpA
responses comparable to those observed to occur in individuals
recovering from wild-type cholera, either because they contain
minimal TcpA (killed oral vaccines) or because they are de-
leted for cholera toxin (live attenuated oral vaccines). This
deletion removes the immunoadjuvant properties of cholera
toxin compared to natural disease and may alter in vivo ex-
pression of other key proteins important to protective immu-
nity following oral immunization.
In an effort to induce anti-TcpA responses, we thus investi-
gated transcutaneous immunization, since this technology is
simple, can be used to induce immune responses against se-
lected important antigens, has been used to induce immune
responses in humans, does not require the use of needles, and
could be practical for development in the developing world,
where cholera is endemic. We were able to establish that anti-
FIG. 3. Survival rates of neonatal CD-1 mice following oral chal-
lenge with wild-type El Tor Inaba V. cholerae N16961. We first estab-
lished that 2  106 CFU of V. cholerae strain N16961 represented one
LD50 in offspring born to unimmunized adult mice (described in the
text). Infant mice were then delivered from dams immunized either
with TcpA plus immunoadjuvant CT or with CT alone. Three- to
five-day-old pups (total, n  87; cohort immunized with CT alone, n 
22; cohort immunized with CT and TcpA, n  65) were gavaged with
2  106 CFU of V. cholerae strain N16961. Challenged mice were kept
at 30°C and monitored for death every 3 to 6 h starting 18 h after oral
challenge. Comparison of survival curves for CT versus TcpA and CT
showed a P value of 	0.001 (log rank test).
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TcpA immune responses could be induced following coappli-
cation of TcpA and cholera toxin to the skin of mice and that
immune responses were protective in a mouse cholera chal-
lenge model. Whether such protection in neonatal pups re-
lated to the effects of transplacental antibodies or antibodies in
breast milk of immunized dams is currently unclear. Of note,
Wu et al. (42) also found protection to occur in offspring of
dams immunized parenterally with a TcpA pilin peptide poly-
mer and adjuvant, although there were measurable IgA re-
sponses in vaccinated dams in this experiment. Also, a number
of researchers have assayed protection in neonatal mice by
using passively administered convalescent-phase sera from im-
munized and unrelated adult mice (the neonates were, there-
fore, not ingesting breast milk of immunized dams, suggesting
that protection was present in the serum fraction) (2, 5). In the
latter experiments, convalescent-phase sera of immunized an-
imals were mixed with the V. cholerae challenge inoculum prior
to oral administration to neonates. Previous investigators have
also shown that mixing purified anti-V. cholerae IgG with the
oral inoculum is protective (17) and that neonatal intestines
contain Fc receptors that mediate bidirectional transport of
serum IgG into the intestinal lumen (43). Since V. cholerae is a
noninvasive organism, our results suggest that protection may
reflect the presence of serum antibodies in the intestinal lu-
mina of neonatal mice via the Fc receptor-mediated transpor-
tation or the presence in intestinal lumina of unassayed anti-
bodies in ingested breast milk.
Interestingly, although transcutaneous application of CT in-
duced serum IgA responses in addition to IgG responses in our
experiment, transcutaneous application of TcpA did not in-
duce serum IgA responses, despite induction of prominent
anti-TcpA IgG responses. We found that additional immuni-
zations with TcpA did not alter this observation. In this exper-
iment, we were also unable to detect significant anti-TcpA or
anti-CT IgA responses in stool samples of immunized animals.
Despite these observations, transcutaneous immunization has
been used previously to elicit mucosal immune responses, as
evidenced by the detection of IgA antibody-secreting cells in
circulation 1 week after topical application and subsequent
secretory IgA antibody in a variety of mucosal sites in animals
and humans (14, 44).
In this feasibility study, we did not evaluate various doses or
immunization regimens; however, previous work has found
induction of immune responses following transcutaneous im-
munization with as little as 1 g of antigen and 10 g of
immunoadjuvant (13, 29). Previous work has also shown that,
when antigen is used alone, three or four transcutaneous ap-
plications of antigen are usually required to induce immune
responses to topically applied antigens (10, 12, 14). In the
present study, we observed a similar result, i.e., three transcu-
taneous applications of TcpA and CT were required to induce
anti-TcpA immune responses in mice. We have shown previ-
ously with mice that the combination immunization strategy of
priming with an oral, live, attenuated V. cholerae vaccine fol-
lowed by transcutaneous immunization with a purified antigen
induces prominent systemic and mucosal immune responses
(20), suggesting that the combination of oral cholera vaccine
administration and transcutaneous immunization with TcpA
may warrant further evaluation. In summary, our current find-
ings suggest that transcutaneous immunization with TcpA is
feasible, immunogenic, and protective in mice. The role of
anti-TcpA responses in the development of an optimal cholera
vaccine warrants further investigation.
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